Insulet Corporation (PODD) Initiates Voluntary Correction For Certain Omnipod Devices

Insulet Corporation (NASDAQ:PODD) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. The company is carrying out a voluntary correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System, it said on May 26.

Insulet Corporation (PODD) Initiates Voluntary Correction For Certain Omnipod Devices

The medical device maker said it had identified a manufacturing issue during monitoring that could result in patients receiving less insulin than required, which could lead to high glucose levels and serious medical conditions like diabetic ketoacidosis (DKA).

According to Insulet Corporation’s (NASDAQ:PODD) press release, the manufacturing issue may cause insulin leakage outside the pod due to a small tear in the cannula above the skin, instead of being fully delivered into the body. This case is separate from a correction issued in March affecting certain Omnipod 5 Pods.

In other news, a Washington-based appeals court on Thursday reversed a $59 million verdict it had given in favor of Insulet against EOFlow for allegedly stealing trade secrets, after finding that the company had taken too long to bring the lawsuit against its Korean rival.

Insulet Corporation (NASDAQ:PODD) is a medical device company focused on developing, manufacturing, and selling insulin delivery systems for patients with diabetes.

While we acknowledge the risk and potential of PODD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PODD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Performing Defense Stocks So Far in 2026 and 10 Stocks That Will Make You Rich Over the Next Decade.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1